Yes, Jardiance (empagliflozin) is FDA-approved for the treatment of type 2 diabetes mellitus.
Jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1. This is a primary FDA-approved indication for the medication, making it a legitimate treatment option for diabetes management.
Mechanism and Glycemic Efficacy
Jardiance works by inhibiting SGLT2 (sodium-glucose cotransporter-2) in the renal proximal tubule, blocking up to 90% of filtered glucose reabsorption and promoting urinary glucose excretion 2. This insulin-independent mechanism provides:
- HbA1c reduction of 0.48-0.84% depending on dose (10 mg or 25 mg) 2
- 35-60% of patients achieve HbA1c <7% at higher doses 2
- Minimal hypoglycemia risk when used alone, though risk increases when combined with insulin or sulfonylureas 2
Dosing for Diabetes
The recommended starting dose is 10 mg once daily, which can be increased to 25 mg once daily in patients who tolerate the medication and require additional glycemic control 1. The medication should be taken in the morning, with or without food.
Beyond Glycemic Control
While Jardiance is definitively indicated for diabetes, its benefits extend significantly beyond glucose lowering:
- Reduces cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease 3
- Reduces heart failure hospitalization by 35% 4
- Provides renal protection and slows chronic kidney disease progression 3
- Modest weight loss of approximately 2 kg 5
- Blood pressure reduction of approximately 4 mmHg systolic and 2 mmHg diastolic 5
Important Prescribing Considerations
Renal function requirements:
- Do not initiate if eGFR <45 mL/min/1.73 m² 1
- Discontinue if eGFR persistently <45 mL/min/1.73 m² 1
- Contraindicated in severe renal impairment, end-stage renal disease, or dialysis 1
Common adverse effects:
- Genital mycotic infections (10-15% in women, higher in uncircumcised men) - typically manageable with antifungals without discontinuation 3
- Mild urinary tract infections 5
- Volume depletion/hypotension risk - assess volume status before initiating, especially in elderly or those on diuretics 1
Critical safety warning:
- Contraindicated in type 1 diabetes due to ketoacidosis risk 3, 1
- Not indicated for diabetic ketoacidosis treatment 1
Clinical Positioning
Current guidelines strongly recommend SGLT2 inhibitors like empagliflozin for patients with type 2 diabetes and established atherosclerotic cardiovascular disease to reduce cardiovascular events and heart failure hospitalization 3. The decision to use empagliflozin should be considered independently of baseline HbA1c or individualized HbA1c target in high-risk individuals 6.